Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; lactic acid as sodium 1.68 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 13.6 g/l; calcium chloride dihydrate 0.184 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; glucose monohydrate (as anhydrous) 22.7 g/l; calcium chloride dihydrate 0.184 g/l; lactic acid as sodium 1.68 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium bicarbonate 2.10 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Canada - English - Health Canada

baxter corporation - magnesium chloride; sodium chloride; lactic acid; sodium bicarbonate - solution - 0.108g; 6.449g; 0.284g; 58.8g - magnesium chloride 0.108g; sodium chloride 6.449g; lactic acid 0.284g; sodium bicarbonate 58.8g - hemodialysis solution

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), lactic acid, unspecified form (unii: 33x04xa5at) (lactic acid, unspecified form - unii:33x04xa5at), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - calcium chloride 0.184 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. phoxillum and prismasol replacement solutions are contraindicated in patients with known hypersensitivities to these products. prismasol and phoxillum are pharmacologically inactive solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. animal reproduction studies have not been conducted with prismasol and phoxillum solutions. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant. safety and effectiveness have been established based on published clinical data of crrt replacement solutions with compositions similar to prismasol and phoxillum used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old. the experience with prismasol and phoxillum solutions in geriatric patients has not identified novel concerns.

Canada - English - Health Canada

baxter corporation - calcium chloride; magnesium chloride; lactic acid; sodium chloride; sodium bicarbonate - solution - 5.145g; 2.033g; 5.4g; 6.45g; 3.09g - calcium chloride 5.145g; magnesium chloride 2.033g; lactic acid 5.4g; sodium chloride 6.45g; sodium bicarbonate 3.09g - hemodialysis solution

New Zealand - English - Medsafe (Medicines Safety Authority)

vantive limited - calcium chloride dihydrate 5.145 g;  ; lactic acid 5.4 g equivalent to lactic acid solution 90% w/w 6 g; magnesium chloride hexahydrate 2.033 g;  ; sodium bicarbonate 3.09 g; sodium chloride 6.45 g;   - dialysis solution - active: calcium chloride dihydrate 5.145 g   lactic acid 5.4 g equivalent to lactic acid solution 90% w/w 6 g magnesium chloride hexahydrate 2.033 g   excipient: water for injection active: sodium bicarbonate 3.09 g sodium chloride 6.45 g   excipient: carbon dioxide water for injection

Canada - English - Health Canada

baxter corporation - calcium chloride; magnesium chloride; dextrose anhydrous; l-lactic acid; sodium chloride; sodium bicarbonate; potassium chloride - solution - 5.145g; 2.033g; 22.00g; 5.400g; 6.450g; 3.090g; 0.157g - calcium chloride 5.145g; magnesium chloride 2.033g; dextrose anhydrous 22.00g; l-lactic acid 5.400g; sodium chloride 6.450g; sodium bicarbonate 3.090g; potassium chloride 0.157g - hemodialysis solution

Canada - English - Health Canada

baxter corporation - calcium chloride; magnesium chloride; dextrose anhydrous; l-lactic acid; sodium chloride; sodium bicarbonate; potassium chloride - solution - 5.145g; 2.033g; 22.00g; 5.400g; 6.450g; 3.090g; 0.314g - calcium chloride 5.145g; magnesium chloride 2.033g; dextrose anhydrous 22.00g; l-lactic acid 5.400g; sodium chloride 6.450g; sodium bicarbonate 3.090g; potassium chloride 0.314g - hemodialysis solution

United States - English - NLM (National Library of Medicine)

mylan institutional llc - magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838) - magnesium chloride 200 mg in 1 ml - as an electrolyte replenisher in magnesium deficiencies. magnesium chloride injection should not be administered if there is renal impairment, marked myocardial disease or to comatose patients.

United States - English - NLM (National Library of Medicine)

gambro renal products - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium phosphate, dibasic (unii: gr686lba74) (sodium cation - unii:lyr4m0nh37, phosphate i - calcium chloride 0.139 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances.they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. none pregnancy category c animal reproduction studies have not been conducted with prismasol and phoxillum solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm, or affect reproductive capacity. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-